| Literature DB >> 35517924 |
Shijiao Sun1, Ming Guan1, Chang Guo2, Li Ma1, Hao Zhou3, Xiaomei Wang1, Fang Mi1,4, Jiutong Li3.
Abstract
As common psychotropic drugs, ketamine (KET) and amphetamine (AMP) are often consumed by drug users at the same time, which seriously threatens people's health. Therefore, the study of simultaneous detection methods for KET and AMP is imperative. In this study, a novel method for the simultaneous detection of KET and AMP in serum was established on the basis of surface-enhanced Raman scattering (SERS). The antibodies were attached on Au@Ag core-shell nanoparticles embedded with different Raman reporters as the detection substrates. The labelled antigens KET-BSA and AMP-BSA were linked to carboxyl magnetic beads, and by adopting the principle of competitive immunoassay, the quantitative detections of ketamine and amphetamine were realized at the same time by detecting the Raman signals at different characteristic peaks on the magnetic beads. A good correlation was shown between ketamine and amphetamine and Raman signal response values were in the concentration range of 0-60 ng mL-1 and 0-200 ng mL-1, and the limits of detection were 1.64 and 2.44 ng mL-1. This method had the advantages of simple, rapid operation, and high sensitivity, and can realise double indicator simultaneous detection, which provided a more favorable scientific basis for preventing or reducing drug abuse, and identifying and monitoring drug users. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35517924 PMCID: PMC9057015 DOI: 10.1039/d0ra06839j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Schematic representation of simultaneous detection of KET and AMP-based on SERS.
KET and AMP series mixed standard solution concentration
| Sample number | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| KET (ng mL−1) | 0 | 5 | 10 | 20 | 40 | 60 |
| AMP (ng mL−1) | 0 | 10 | 20 | 50 | 100 | 200 |
Fig. 2UV spectra of Au NPs, Au-4MBA@Ag and Au-XP013@Ag (a), Raman spectra of Au-4MBA@Ag and Au-XP013@Ag (b), particle size distributions of Au NPs and Au-reporters@Ag (c), TEM of Au NPs (d), Au-4MBA@Ag (e) and Au-XP013@Ag (f).
Raman signal values of KET series concentration (n = 3)
| Concentration (ng mL−1) | 0 | 5 | 10 | 20 | 40 | 60 |
|---|---|---|---|---|---|---|
| Raman intensity | 25 709 ± 871.1 | 16 725 ± 734.7 | 11 118 ± 1486 | 6251 ± 1057 | 4866 ± 666.5 | 2932 ± 489.9 |
Raman signal values of AMP series concentration (n = 3)
| Concentration (ng mL−1) | 0 | 10 | 20 | 50 | 100 | 200 |
|---|---|---|---|---|---|---|
| Raman intensity | 25 144 ± 982.9 | 19 464 ± 1561 | 16 707 ± 229.4 | 11 127 ± 585.2 | 7615 ± 619.0 | 5257 ± 204.3 |
Fig. 3Standard curve of KET (a), AMP (b), and Raman spectra of standard curves of KET and AMP (c).
Comparison of ketamine and Amphetamine detection performances in different methods
| Methods | Sample matrix | LODs | Refs | |
|---|---|---|---|---|
| Ketamine | LC-MS-MS | Urine | 1.00 ng mL−1 |
|
| Flurescence genosensor | Blood | 0.06 ng mL−1 |
| |
| WT-ESI-MS | Urine | 20.0 ng mL−1 |
| |
| SERS | Anesthetic | 27 ng mL−1 |
| |
| This study | Serum | 1.64 ng mL−1 | — | |
| Amphetamine | GC-MS | Urine | 5.00 ng mL−1 |
|
| LC-MS-MS | Urine | 5.00 ng mL−1 |
| |
| SERS | Urine | 50 ng mL−1 |
| |
| This study | Serum | 2.44 ng mL−1 | — |
Spike recovery experiment (n = 3)
| Theoretical value (ng mL−1) | Raman intensity | Measured value (ng mL−1) | Recovery rate (%) | |
|---|---|---|---|---|
| C1 | 36.4 | 3769 ± 384.0 | 33.6 ± 7.5 | 92.4 |
| 45.5 | 15 209 ± 1181 | 37.6 ± 6.2 | 82.8 | |
| C2 | 18.6 | 5656 ± 390.9 | 15.7 ± 1.9 | 84.3 |
| 45.5 | 14 543 ± 861.9 | 40.9 ± 4.6 | 90.2 | |
| C3 | 18.2 | 5194 ± 654.5 | 18.6 ± 3.7 | 102.0 |
| 63.6 | 11 890 ± 622.7 | 59.9 ± 5.9 | 94.2 | |
| C4 | 18.2 | 5069 ± 397.0 | 19.1 ± 2.8 | 105.1 |
| 45.9 | 13 113 ± 2328 | 51.9 ± 15.3 | 113.2 |
Precision experiment (n = 10)
| Sample number |
| Raman intensity | Measured value (ng mL−1) | CV (%) | |
|---|---|---|---|---|---|
| The first batch | 2 | 5 | 14 933 ± 888.9 | 5.4 ± 0.5 | 9.9 |
| 10 | 23 448 ± 480.8 | 12.9 ± 1.9 | 15.0 | ||
| 4 | 20 | 5562 ± 611.4 | 19.6 ± 2.9 | 14.6 | |
| 50 | 16 183 ± 1143 | 53.2 ± 8.6 | 16.2 | ||
| 6 | 60 | 3541 ± 174.6 | 50.9 ± 10.4 | 20.4 | |
| 200 | 10 090 ± 725.1 | 159.9 ± 27.9 | 17.4 | ||
| The second batch | 2 | 5 | 17 048 ± 1401 | 4.7 ± 0.9 | 20.0 |
| 10 | 19 500 ± 986.8 | 11.7 ± 2.4 | 21.2 | ||
| 4 | 20 | 7712 ± 1002 | 17.6 ± 3.3 | 18.7 | |
| 50 | 11 383 ± 1055 | 49.1 ± 8.7 | 17.8 | ||
| 6 | 60 | 3390 ± 286.1 | 55.3 ± 8.2 | 14.8 | |
| 200 | 5785 ± 230.2 | 166.5 ± 13.5 | 8.1 | ||
| The third batch | 2 | 5 | 17 538 ± 942.0 | 3.9 ± 0.7 | 19.0 |
| 10 | 16 083 ± 697.3 | 9.0 ± 1.6 | 18.5 | ||
| 4 | 20 | 8708 ± 352.5 | 17.7 ± 1.0 | 6.2 | |
| 50 | 10 194 ± 686.3 | 35.1 ± 5.5 | 15.6 | ||
| 6 | 60 | 3797 ± 325.0 | 52.8 ± 5.4 | 10.2 | |
| 200 | 4921 ± 244.6 | 176.9 ± 22.3 | 12.6 | ||
| Inter-batch | 2 | 5 | 16 506 ± 1384 | 4.9 ± 0.8 | 17.0 |
| 10 | 19 677 ± 3685 | 11.2 ± 1.9 | 17.7 | ||
| 4 | 20 | 7327 ± 1607 | 18.3 ± 1.1 | 6.1 | |
| 50 | 12 586 ± 3170 | 45.8 ± 9.5 | 20.7 | ||
| 6 | 60 | 3576 ± 205.8 | 53.0 ± 2.2 | 4.1 | |
| 200 | 6932 ± 2769 | 167.8 ± 8.5 | 5.0 |
Interfering experiment (n = 3)
| Interfering substances | Sample number |
| Raman intensity | Measured value (ng mL−1) | Recovery rate (%) |
|---|---|---|---|---|---|
| Bilirubin | 2 | 5 | 17 193 ± 965.9 | 4.2 ± 0.8 | 85.9 |
| 10 | 26 595 ± 1473 | 9.4 ± 4.3 | 94.1 | ||
| 4 | 20 | 9196 ± 889.8 | 16.5 ± 2.7 | 82.8 | |
| 50 | 17 011 ± 647.2 | 50.5 ± 4.8 | 101.1 | ||
| 6 | 60 | 4557 ± 598.6 | 58.8 ± 14.7 | 98.0 | |
| 200 | 8339 ± 588.1 | 176.0 ± 15.2 | 88.0 | ||
| EDTA | 2 | 5 | 16 307 ± 711.0 | 5.0 ± 0.6 | 100.8 |
| 10 | 25 670 ± 1202 | 10.1 ± 3.3 | 101.2 | ||
| 4 | 20 | 8050 ± 1194 | 21.0 ± 4.8 | 105.1 | |
| 50 | 16 137 ± 434.1 | 57.3 ± 3.5 | 114.8 | ||
| 6 | 60 | 4870 ± 876.0 | 52.9 ± 17.0 | 88.1 | |
| 200 | 8049 ± 614.9 | 184.0 ± 16.6 | 92.0 | ||
| Trisodium citrate | 2 | 5 | 15 469 ± 979.9 | 5.8 ± 0.9 | 116.9 |
| 10 | 24 985 ± 383.7 | 11.9 ± 1.1 | 119.0 | ||
| 4 | 20 | 8883 ± 154.1 | 17.3 ± 0.4 | 86.6 | |
| 50 | 16 135 ± 793.6 | 57.5 ± 6.4 | 115.0 | ||
| 6 | 60 | 4828 ± 307.6 | 50.3 ± 5.9 | 83.9 | |
| 200 | 8593 ± 626.1 | 169.5 ± 16.0 | 84.7 | ||
| Hemoglobin | 2 | 5 | 15 321 ± 1193 | 6.0 ± 1.1 | 120.3 |
| 10 | 25 156 ± 1009 | 11.5 ± 2.8 | 115.1 | ||
| 4 | 20 | 7603 ± 722.2 | 24.0 ± 4.4 | 120.0 | |
| 50 | 15 929 ± 756.6 | 59.2 ± 6.6 | 118.5 | ||
| 6 | 60 | 4533 ± 331.1 | 64.3 ± 8.4 | 107.3 | |
| 200 | 8641 ± 301.7 | 167.8 ± 7.6 | 83.9 |
Fig. 4Specificity experiment (n = 3).
Fig. 5Comparison of SERS and LC-MS/MS method for the simultaneous detection of KET (a) and AMP (b).